EpiPens

Mylan is recalling some EpiPens distributed between December 2015 and July 2016, saying a potentially defective part could make them fail to activate during a life-threatening allergic reaction.

The Auvi-Q epinephrine injector was pulled from the market in 2015 because of quality concerns. Now, the drug's maker says the problems have been solved and Auvi-Q will be available again in 2017.

In testimony prepared for a congressional hearing, Mylan CEO Heather Bresch says the company makes about $50 in profit on each EpiPen. Analysts say it's still a hefty margin.

The company's lobbying of state legislatures is just one factor in EpiPen's dominance of the market. Manufacturers of competing devices have struggled to gain a foothold.

Mylan's move comes amid pressure from consumers and Congress to lower the allergy drug's price. In less than 10 years, the price has risen from about $100 to more than $600 for an injector two-pack.

EpiPen, the new poster child for prescription drug price gouging, may find that offering discount coupons isn't enough to mollify its critics in Congress and online.

Lawmakers are demanding answers as to why the price of EpiPens, which are used to stop life-threatening allergic reaction, keeps going up. The company said Thursday it will reimburse some of the cost.